CatalystMarker
Sign in
← board

IQV

distress 1/10 · well-funded / low risk
$207.90+5%today-15% from 52w high
iqvia.com93,000 employeesDurham, NCDiagnostics & Research
Revenue
$4151M
Liquidity
$2103M
Runway
Shares 1y
-2%

Price & events

-13.0% over 6M
$157$199$241Jan 26Apr 26Jul 267.1Mfinancing: 8-K material_agreement (2026-06-11)rating: Mizuho: Outperform (2026-07-13)rating: Baird: Outperform (2026-07-01)rating: Morgan Stanley: Overweight → Equal-Weight (2026-06-17)rating: Evercore ISI Group: Outperform (2026-04-08)rating: TD Cowen: Hold → Buy (2026-03-09)rating: Barclays: Equal-Weight → Overweight (2026-03-06)rating: RBC Capital: Outperform (2026-03-03)rating: Truist Securities: Buy (2026-02-19)
CatalystRating changeDilutionFinancingdashed = today
+4.7%
1D
-1.2%
1W
+21.4%
1M
+29.4%
3M
-11.6%
6M
+7.0%
1Y
-12.9%
2Y
-16.5%
5Y
+17.7%
All

Overview

Market Cap
$34.70B
Enterprise Value
$46.74B
Volume
136.44K
52 Week Range
$157 – $244
Total Shares
166.90M
Float Shares
158.55M
Short %
3.45%
% Held by Insiders
1.08%
% Held by Institutions
104.09%
RVOL
0.10x
Beta
1.20

Pipeline · 0 trials · 0 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
No pipeline trials tracked.

Catalyst news & presentations · 1

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: 166,900,000 · 0 offerings/1y · 0 PIPEs
  • 2026-06-118-Kmaterial_agreement
  • 2025-12-098-Kmaterial_agreement
  • 2025-06-048-Kmaterial_agreement
  • 2025-03-108-Kmaterial_agreement
  • 2024-08-15SC 13Gstrategic_stake
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

strong buy · target $232 (+12% upside) · 19 analysts
  • 2026-07-13MizuhoOutperform
  • 2026-07-01BairdOutperform
  • 2026-06-17Morgan StanleyOverweight → Equal-Weight
  • 2026-04-08Evercore ISI GroupOutperform
  • 2026-03-09TD CowenHold → Buy
  • 2026-03-06BarclaysEqual-Weight → Overweight

Competitors

  • none identified

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.